Topic: Pulmonary Hypertension


9. Letairis

Gilead’s recent troubles in hepatitis C aside, the company isn't challenge-free. It has a big patent loss coming this year for Letairis, approved in 2007 and used to treat pulmonary arterial hypertension.
Patents on file

Top 10 U.S. patent losses of 2017

Among the many meds that’ll lose patent protection in the U.S. this year are 10 drugs that each contribute in a big way for top drugmakers. Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead Sciences are set to hit the patent cliff this year with some of their respective big sellers.